- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
An association between brain volume, in particular the size of one’s hippocampi, and one’s memory, could predict one’s likelihood of cognitive impairment, such as dementia.
Levels of Chitinase-3-like protein 1 (YKL-40) are higher in mild cognitive impairment and Alzheimer’s disease patients; increased levels of YKL-40 and Visinin-like protein-1 (VILIP-1) may be associated with disease progression.
In this review, Walker and Lue evaluate which markers might better define different activation phenotypes of microglia in human brains and whether they fit into current microglial polarization schemes.
Those with type 2 diabetes, younger males with high non-diabetic HbA1c and adults with high stable blood glucose are at increased risk of poorer cognition and potentially increased risk of cognitive impairment.
Ottavio Arancio and colleagues summarise recent studies on human induced pluripotent stem cell (iPSC)-derived neurons and evaluate their use as a model for neurological diseases.
Craig W Ritchie, Graciela Terrera, Terence J QuinnAlzheimer's Research & Therapy 2015, 7:31 (18 March 2015)
News from Alzforum
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
The 31st International Conference of Alzheimer’s Disease International
Alzheimer’s Research and Therapy is associated to Alzheimer’s Disease International (ADI) and is pleased to announce that the 31st International Conference of Alzheimer’s Disease International, will be held at the Budapest Conference Center (Hungary) from 21 – 24 April 2015.
Submit your abstract now and be a part of ADI’s leading international dementia conference. A broad range of topics, including, research, care and policy issues means there is something for everyone. You have the opportunity to share your latest study with a global and diverse audience, ensuring your voice is heard by leaders in the field.
Register now to benefit from the early bird discount and to be part of the ADI 2016 conference.
Abstract submission: Monday 16 November 2015
Early Bird Deadline: Sunday 31 January 2015
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.